Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Herbertson, Rebecca A ^a   Karapetis, C ^b   Pavlakis, N ^b   Price, T ^b   Tebbutt, N ^b  

^a AUSTIN HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ACNE; ANOREXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; FATIGUE; HUMAN; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; LUNG FIBROSIS; METASTASIS; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SEPSIS;

EID: 44949192096     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007047     Document Type: Review

References (19)

1. Choti 2002 Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al.Trends in long-term survival following liver resection for hepatic colorectal metastases. Annals of Surgery 2002;235(6):759-66.
2. Chung 2005 Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al.Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005;23(9):1803-10.
3. Cunningham 2004 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004;351(4):337-345.
4. Fernlay 2004 Fernlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IACR Cancer Base: IACR Press 2004.
5. Giantonio 2006 Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A Phase II study of high-dose bevacizumab in combination with irinotecan, 5-flurouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E2200. Annals of Oncology 2006;17(9):1399-403.
6. Giantonio 2007 Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 2007;25(12):1539- 44.
7. Grothey 2004 Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Journal of Clinical Oncology 2004;22(7):1209- 1214.
8. Hurwitz 2004 Hurwitz HI, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth JD, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004;350(23):2335-42.
9. Hurwitz 2005 Hurwitz HI, Fehrenbacher L, Hainsworth JD, Berlin J, Holmgren E, et al.Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first line metastatic colorectal cancer. Journal of Clinical Oncology 2005;23(15):3502-8.
10. Jonker 2007 Jonker DJ, O'Callaghan, CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore M. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007;357(20):2040-8.
11. Kuo 2005 Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, et al.Phase II study of gefitinib, fluorouracil. leucovorin, and oxaliplation therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology 2005;23(24):5613-9.
12. Mackenzie 2005 Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, et al.A phase II trial of ZD1839 (Iressa) 750mg per day, an oral epidermal growth factor recepto-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005;23(2):165-70.
13. Mayer 1993 Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71(8):2454-60.
14. Messa 1998 Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncologica 1998;37(3):285-289.
15. Meyerhardt 2007 Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Annals of Oncology 2007;18(7):1185-9.
16. Salomon 1995 Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology 1995;19(3):183-232.
17. Scartozzi 2004 Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related-metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. Journal of Clinical Oncology 2004;22(23):4772-4778.
18. van Cruijsen 2005 van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptors and angiogenesis: Opportunities for combined anticancer strategies. International Journal of Cancer 2005;117(6):883-8.
19. Wainberg 2006 Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clinical Colorectal Cancer 2006;5(5):363-367.